Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common end-of-life condition for patients with advanced cancers, compared with haloperidol alone, according to a study led by researchers at The University of Texas MD Anderson Cancer Center.
Gabriele Casirati, of Boston Children’s Hospital, Susan E. De Wolf, of Memorial Sloan Kettering Cancer Center, Stephen Persaud, of Washington University School of Medicine, and Abdur Rehman, of the University of Texas MD Anderson Cancer Center, were awarded DKMS’ research grant in honor of John A. Hansen.
